表紙:抗真菌剤の世界市場(2022年~2028年)
市場調査レポート
商品コード
1215732

抗真菌剤の世界市場(2022年~2028年)

Antifungal Agent Market 2022-2028

出版日: | 発行: Orion Market Research | ページ情報: 英文 | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.96円
抗真菌剤の世界市場(2022年~2028年)
出版日: 2023年01月14日
発行: Orion Market Research
ページ情報: 英文
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の抗真菌剤の市場規模は、予測期間中に3.1%のCAGRで大きく成長すると予測されています。

近年、真菌感染症は世界的に大きな健康問題となっており、院内感染の発生が市場拡大に拍車をかけています。また、がん・造血幹細胞移植の増加など、免疫系が損なわれていることが院内感染の増大に繋がり、免疫力の低下によって真菌感染症が増加し、市場拡大を促進しています。一方、真菌感染症の日常的な治療へのジェネリック医薬品・高価な医薬品の多用、抗真菌剤の重大な副作用、政府による規制が、市場拡大の妨げになる見通しです。

当レポートでは、世界の抗真菌剤市場について調査分析し、市場概要、セグメント・地域別の市場分析、競合情勢、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向

第3章 競合情勢

  • Gilead Sciences, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • 主要戦略分析
  • 主要企業に対するCOVID-19の影響

第4章 市場内訳

  • 世界の抗真菌剤市場:薬剤クラス別
    • ポリエン
    • エキノカンジン
    • アリルアミン
    • アゾール
  • 世界の抗真菌剤市場:投薬タイプ別
    • 粉末
    • 軟膏
    • 薬剤
  • 世界の抗真菌剤市場:投与経路別
    • 非経口
    • 局所
    • 経口

第5章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • その他の地域

第6章 企業プロファイル

  • Abbott Laboratories, Inc.
  • Astellas Pharma Inc.
  • Basilea Pharmaceutica Ltd.
  • Bayer Healthcare LLC
  • Bristol-Myers Squibb Co.
  • Cadila Healthcare Ltd.
  • Cosmo Pharmaceuticals N.V.
  • Dr. Reddy's Laboratories Ltd.
  • Enzon Pharmaceuticals, Inc
  • Janssen Pharmaceutica NV
  • Mayne Pharma Group Ltd.
  • SCYNEXIS, Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
図表

LIST OF TABLES

  • 1. GLOBAL ANTIFUNGAL AGENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
  • 2. GLOBAL POLYENE ANTIFUNGAL AGENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL ECHINOCANDINS ANTIFUNGAL AGENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL ALLYLAMINES ANTIFUNGAL AGENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL AZOLE ANTIFUNGAL AGENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL ANTIFUNGAL AGENT MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2021-2028 ($ MILLION)
  • 7. GLOBAL POWDER ANTIFUNGAL AGENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBAL OINTMENT ANTIFUNGAL AGENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 9. GLOBAL DRUGS ANTIFUNGAL AGENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL ANTIFUNGAL AGENT MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
  • 11. GLOBAL ANTIFUNGAL AGENT MARKET BY PARENTERAL RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 12. GLOBAL ANTIFUNGAL AGENT MARKET BY TOPICAL RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 13. GLOBAL ANTIFUNGAL AGENT MARKET BY ORAL RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 14. GLOBAL ANTIFUNGAL AGENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
  • 15. NORTH AMERICAN ANTIFUNGAL AGENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 16. NORTH AMERICAN ANTIFUNGAL AGENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
  • 17. NORTH AMERICAN ANTIFUNGAL AGENT MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2021-2028 ($ MILLION)
  • 18. NORTH AMERICAN ANTIFUNGAL AGENT MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
  • 19. EUROPEAN ANTIFUNGAL AGENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 20. EUROPEAN ANTIFUNGAL AGENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
  • 21. EUROPEAN ANTIFUNGAL AGENT MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2021-2028 ($ MILLION)
  • 22. EUROPEAN ANTIFUNGAL AGENT MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
  • 23. ASIA-PACIFIC ANTIFUNGAL AGENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 24. ASIA-PACIFIC ANTIFUNGAL AGENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
  • 25. ASIA-PACIFIC ANTIFUNGAL AGENT MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2021-2028 ($ MILLION)
  • 26. ASIA-PACIFIC ANTIFUNGAL AGENT MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)
  • 27. REST OF THE WORLD ANTIFUNGAL AGENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 28. REST OF THE WORLD ANTIFUNGAL AGENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021-2028 ($ MILLION)
  • 29. REST OF THE WORLD ANTIFUNGAL AGENT MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2021-2028 ($ MILLION)
  • 30. REST OF THE WORLD ANTIFUNGAL AGENT MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL ANTIFUNGAL AGENT MARKET, 2021-2028 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL ANTIFUNGAL AGENT MARKET BY SEGMENT, 2021-2028 ($ MILLION)
  • 3. RECOVERY OF GLOBAL ANTIFUNGAL AGENT MARKET, 2022-2028 (%)
  • 4. GLOBAL ANTIFUNGAL AGENT MARKET SHARE BY DRUG CLASS, 2021 VS 2028 (%)
  • 5. GLOBAL POLYENE ANTIFUNGAL AGENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBAL ECHINOCANDINS ANTIFUNGAL AGENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 7. GLOBAL ALLYLAMINES ANTIFUNGAL AGENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 8. GLOBAL AZOLE ANTIFUNGAL AGENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 9. GLOBAL ANTIFUNGAL AGENT MARKET SHARE BY DOSAGE TYPE, 2021 VS 2028 (%)
  • 10. GLOBAL POWDER ANTIFUNGAL AGENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 11. GLOBAL OINTMENT ANTIFUNGAL AGENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 12. GLOBAL DRUGS ANTIFUNGAL AGENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 13. GLOBAL ANTIFUNGAL AGENT MARKET SHARE BY ROUTE OF ADMINISTRATION, 2021 VS 2028 (%)
  • 14. GLOBAL ANTIFUNGAL AGENT BY PARENTERAL MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 15. GLOBAL ANTIFUNGAL AGENT BY TOPICAL MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 16. GLOBAL ANTIFUNGAL AGENT BY ORAL MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 17. GLOBAL ANTIFUNGAL AGENT MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 18. US ANTIFUNGAL AGENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. CANADA ANTIFUNGAL AGENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. UK ANTIFUNGAL AGENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. FRANCE ANTIFUNGAL AGENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. GERMANY ANTIFUNGAL AGENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. ITALY ANTIFUNGAL AGENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. SPAIN ANTIFUNGAL AGENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. REST OF EUROPE ANTIFUNGAL AGENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. INDIA ANTIFUNGAL AGENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. CHINA ANTIFUNGAL AGENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 28. JAPAN ANTIFUNGAL AGENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 29. SOUTH KOREA ANTIFUNGAL AGENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 30. REST OF ASIA-PACIFIC ANTIFUNGAL AGENT MARKET SIZE, 2021-2028 ($ MILLION)
  • 31. REST OF THE WORLD ANTIFUNGAL AGENT MARKET SIZE, 2021-2028 ($ MILLION)
目次
Product Code: OMR2026788

Title:Global Antifungal Agent Market Size, Share & Trends Analysis Report By Drug Class (Polyene, Echinocandins, Allylamines, and Azole), By Dosage Form (Powder, Ointment and Drugs), and By Route of Administration (Parenteral, Topical and Oral) Forecast 2022-2028.

The global antifungal agent market is anticipated to grow at a substantial CAGR of 3.1% during the forecast period. Fungal infections have become a major health concern around the globe in recent years. In addition, the occurrence of nosocomial infections is fueling market expansion. Growing cancer occurrences, an increase in hematopoietic stem cell transplantation, and other conditions that impair the immune system are all contributing to the rise of nosocomial infections. As a result of a weakened immune system, fungal infections become more common, fueling market expansion.

On the other hand, the increased availability of generic and pricey medications for the routine treatment of fungal infections is limiting the market growth. Furthermore, the market's expansion is being hampered by the substantial side effects of antifungal medications used to treat fungal infections. Government rules are projected to stifle the market's expansion. For instance, in 2020, the US FDA published guidance on the approval of antibacterial and antifungal drugs. According to the US FDA, antibacterial and antifungal drugs will only be allowed if they are meant to treat a significant life-threatening infection in a small group of patients with unmet needs.

The global antifungal agent market is segmented based on the drug class, dosage form, and routine of administration. Based on the drug class, the market is segmented into polyene, echinocandins, allylamines, and azole. Based on the dosage form, the market is sub-segmented into powder, ointment, and drugs. Based on the routine of administration the market is sub-segmented into parenteral, topical, and oral. The echinocandins category is also driving the growth of the antifungal agent market. The global antifungal medicines market is driven by an increase in the incidence of thrush, also known as oropharyngeal candidiasis, which occurs in the mouth or throat. Echinocandins are caused by the infection, the infection it causes is called candidiasis. Most can be easily treated with over-the-counter or prescription medications which increases the demand for the antifungal market.

Geographically market is segmented into: North America, Europe, Asia Pacific, and the Rest of the World. The market for antifungal medications in North America is one of the largest in the globe. The region's expansion is due to an increase in the occurrence of infectious diseases. The rise in prevalence had heightened the clinical urgency to increase the use of these medications, along with accelerating the development of novel drugs with FDA fast-track authorization. Furthermore, the presence of established pharmaceutical companies that are continually pushing for extensive marketing of their products and expanding their reach is expected to be a crucial factor driving the regional market's expansion.

The major companies serving the global Antifungal agent market include Gilead Sciences, Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers &acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2021, Cadila Pharmaceuticals launched Posaconazole, a novel triazole antifungal medicine that is effective against a wide spectrum of invasive fungal illnesses. In addition, the medication has been recommended as a Mucormycosis second-line treatment.

Research Methodology

The market study of the global antifungal agent market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Antifungal Agent Market Research and Analysis by Drug Class.
  • Global Antifungal Agent Market Research and Analysis by Dosage Form.
  • Global Antifungal Agent Market Research and Analysis by Route of Administration.

The Report Covers:

  • Comprehensive research methodology of the global antifungal agent market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global antifungal agent market.
  • Insights about market determinants that are stimulating the global antifungal agent market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on The Global Antifungal Agent Market
  • Recovery Scenario of Global Antifungal Agent Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. BY Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Gilead Sciences, Inc.
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Merck & Co., Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Novartis AG
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Pfizer Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Sanofi
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Key Strategy Analysis
  • 3.7. Impact of Covid-19 on Key Players

4. Market Segmentation

  • 4.1. Global Antifungal Agents Market By Drug Class
    • 4.1.1. Polyene
    • 4.1.2. Echinocandins
    • 4.1.3. Allylamines
    • 4.1.4. Azole
  • 4.2. Global Antifungal Agents Market By Dosage Type
    • 4.2.1. Powder
    • 4.2.2. Ointment
    • 4.2.3. Drugs
  • 4.3. Global Antifungal Agents Market By Route of Administration
    • 4.3.1. Parenteral
    • 4.3.2. Topical
    • 4.3.3. Oral

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Abbott Laboratories, Inc.
  • 6.2. Astellas Pharma Inc.
  • 6.3. Basilea Pharmaceutica Ltd.
  • 6.4. Bayer Healthcare LLC
  • 6.5. Bristol-Myers Squibb Co.
  • 6.6. Cadila Healthcare Ltd.
  • 6.7. Cosmo Pharmaceuticals N.V.
  • 6.8. Dr. Reddy's Laboratories Ltd.
  • 6.9. Enzon Pharmaceuticals, Inc
  • 6.10. Janssen Pharmaceutica NV
  • 6.11. Mayne Pharma Group Ltd.
  • 6.12. SCYNEXIS, Inc.
  • 6.13. Sumitomo Dainippon Pharma Co., Ltd.
  • 6.14. Sun Pharmaceutical Industries Ltd.
  • 6.15. Teva Pharmaceutical Industries Ltd.
  • 6.16. Viatris Inc.